High Levels of Triggering Receptor Expressed in Myeloid Cells-Like Transcript-1 Positive, but Not Glycoprotein 1b+,

Angelia D Gibson1, Zaida Bayrón-Marrero2, Benjamin Nieves-Lopez3

  • 1Division of Natural Sciences, Maryville College, Maryville, TN.

PubMed
Abstract

Insights

Triggering receptor expressed in myeloid cells-like transcript-1 positive (TLT-1+) microparticles (MPs) are associated with worse outcomes in acute respiratory distress syndrome (ARDS). Higher TLT-1+ MP levels correlate with increased mortality and disease severity in ARDS patients.

Area of Science:

  • Hematology
  • Immunology
  • Critical Care Medicine

Background:

  • Microparticles (MPs) are small vesicles released from cell membranes.
  • Platelet-derived microparticles (PMPs) play roles in hemostasis and inflammation.
  • Triggering receptor expressed in myeloid cells-like transcript-1 (TLT-1) is a protein found on certain cells.

Purpose of the Study:

  • To identify TLT-1 positive (TLT-1+) microparticles (MPs).
  • To evaluate the association between TLT-1+ MPs and clinical outcomes in acute respiratory distress syndrome (ARDS).
  • To assess the relationship between TLT-1+ MPs and ARDS disease severity.

Main Methods:

  • Retrospective cohort study utilizing ARDS Network clinical trial data.
  • Flow cytometry was used to detect TLT-1+ MPs.
  • Quantification of TLT-1, glycoprotein (Gp) 1b, and αIIbβIIIa immunopositive MPs in ARDS patients.

Main Results:

  • TLT-1+ MPs were identified and found to bind fibrinogen.
  • No association was observed between Gp1b+ MPs and clinical outcomes.
  • Higher levels of TLT-1+ MPs correlated significantly with increased mortality, higher Acute Physiology and Chronic Health Evaluation III scores, and a greater likelihood of thrombocytopenia in ARDS patients.

Conclusions:

  • TLT-1+ MPs are associated with mortality and disease severity in ARDS.
  • TLT-1+ MPs showed stronger correlations with clinical outcomes than αIIbβIIIa+ MPs.
  • Further research is warranted to elucidate the mechanistic role of TLT-1+ PMPs in ARDS progression.

Related Concept Videos

Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
201
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
189
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
130